The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.

Affiliation

Research Department of Urology, Division of Surgery and Interventional Science, Faculty of Medicine, University College London, London, UK; Department of Urology, UCLH NHS Foundation Trust, London, UK; Centre for Medical Imaging, Division of Medicine, Faculty of Medicine, University College London, London, UK; Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Imperial Urology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: [Email]

Abstract

Multiparametric magnetic resonance imaging (mpMRI)-targeted prostate biopsies can improve detection of clinically significant prostate cancer and decrease the overdetection of insignificant cancers. It is unknown whether visual-registration targeting is sufficient or augmentation with image-fusion software is needed.

Keywords

Biopsy,Diagnostic imaging,Prostatic neoplasms,

OUR Recent Articles